A guide to treatment with Fabhalta for C3 Glomerulopathy - Patient and Caregivers guide

Confirmation of Vaccination form: In accordance with the RMP, iptacopan can only be dispensed once Novartis receives written confirmation that each patient has received vaccination against N. meningitidis and S. pneumoniae infections and/or receipt of prophylactic antibiotic treatment (in accordance with national guidelines).

Fabhalta Patient Safety Card - C3G indication

This material has been developed and funded by Novartis Pharmaceuticals UK Ltd and is intended only for UK patients with paroxysmal nocturnal haemoglobinuria (PNH) who have been prescribed iptacopan

Vaccination confirmation form - Fabhalta C3G indication

Healthcare Professional’s Guide to FABHALTA for C3G indication

This brochure aims to provide guidance and mitigate possible risk of infections during iptacopan treatment, and haemolysis after discontinuation.

This material has been developed and funded by Novartis Pharmaceuticals UK Ltd and is intended only for UK patients with paroxysmal nocturnal haemoglobinuria (PNH) who have been prescribed iptacopan and their caregivers. This guide aims to provide you with important safety information for iptacopan.